Navigation Links
Late-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care
Date:3/19/2017

WASHINGTON, March 19, 2017 /PRNewswire/ -- New late-breaking featured clinical research presented today adds strong clinical support for Abbott's CardioMEMS HF System as an effective real-world approach to reduce heart failure hospitalizations and combat the rising cost of heart failure. The CardioMEMS HF System is the first and only U.S. Food and Drug Administration-approved monitor that, when used by physicians to manage heart failure, has been shown to significantly reduce heart failure hospital admissions and improve the quality of life in patients with heart failure (NYHA Class III). The latest research includes more than 1,100 Medicare patients and was presented today during the American College of Cardiology (ACC) 66th Annual  Scientific Sessions in Washington, D.C., and simultaneously published in the Journal of the American College of Cardiology (JACC).

Researchers found a 46 percent reduction in heart failure hospitalizations in patients six months after receiving the CardioMEMS HF System, and a 34 percent reduction at 12 months post-implant. The data are consistent with what was seen in the CHAMPION clinical trial, further confirming that when physicians adjust medications based on the patient's pulmonary artery pressures, related hospitalizations are significantly reduced.

"These results support the clinical effectiveness and potential cost savings of using an implantable hemodynamic monitor to help with heart failure management," said Akshay Desai, M.D., director of the Heart Failure Disease Management Program at Brigham and Women's Hospital in Boston, Mass. "Reducing heart failure hospitalizations is an important goal for patients and hospitals alike, and may help to improve long-term clinical outcomes and quality of life for our patients."

The data also showcased important cost-savings captured through reductions in heart failure hospitalizations associated with the use of the CardioMEMS HF System. In particular, in the six months post-implant, each patient had an average reduction of more than $10,500 in comprehensive health care costs compared to the six months prior to implant. Twelve month post-implant analysis showed a $13,190 reduction in costs per patient. 

"The reduction in hospitalizations and costs associated with heart failure confirmed by these data shows that proactive patient management with the CardioMEMS HF System is successful in mainstream practice and results in improved clinical outcomes," said Philip Adamson, M.D., medical director of Abbott's heart failure business. "Success with this technology for us means helping patients get back to living their life."

Data were collected using U.S. Medicare claims from patients undergoing a CardioMEMS sensor implant to measure pulmonary artery pressure, and the rates of heart failure hospitalizations from before and after the implant were compared. Comprehensive heart failure-related costs were also compared. The data confirmed that hemodynamic (pulmonary artery pressure) monitoring with the CardioMEMS HF System in an outpatient setting reduced heart failure hospitalization for patients while also reducing related costs.

Additional data on managing heart failure patients with the CardioMEMS HF System published on Feb. 22, 2017, in CirculationImpact of Practice Based Management of PA Pressures in 2,000 Patients Implanted with the CardioMEMS Sensor—showed that patient compliance and physician-directed management outside of a clinical study led to a significant reduction of pulmonary artery pressures.

About Abbott's Heart Failure Portfolio:
Abbott is pioneering heart failure disease management with innovative solutions like the CardioMEMS HF System, ground-breaking quadripolar pacing technology, our first-to-market MultiPoint pacing technology and, in select European markets, the HeartMate 3 left ventricular assist system. Abbott collaborates with heart failure specialists, clinicians and advocacy partners to provide innovative, cost-effective solutions that help reduce hospitalizations and improve patient quality of life for heart failure patients around the world.

About Abbott:
At Abbott (NYSE: ABT), we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/late-breaking-data-shows-the-cardiomems-hf-system-is-effective-in-reducing-heart-failure-hospitalizations-and-cost-of-care-300425696.html


'/>"/>
SOURCE Abbott
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 American Heart Association (AHA) Scientific Sessions
2. 16 Highly Anticipated Late-Breaking Clinical Trials To Be Presented At VIVA 15
3. CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
4. Cynosure Announces Late-Breaking Abstracts on New Non-Invasive Fat Reduction Technology at ASLMS Annual Conference
5. CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
6. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
7. New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
8. New Data Shows Significant Potential Cost Savings with On-Site Hemodialysis in Skilled Nursing Facilities
9. Exact Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test
10. Landmark Study: Meta-Analysis of 28 Studies Shows Stretta Therapy for GERD Consistently and Significantly Improves Outcomes
11. Study Shows Improved Outcomes With NephroCheck Test For Risk Assessment Of Acute Kidney Injury And KDIGO Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):